Biopharm I-Mab takes steps to become Rockville-based company

I-Mab, a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment, Wednesday announced that as part of its strategy to become a U.S.-based biotech with headquarters in Rockville, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd., an unconsolidated affiliate of the company, and a group of China-based investors to divest the company’s assets and business operations in China.